Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study
NCT ID: NCT01627262
Last Updated: 2016-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
123 participants
INTERVENTIONAL
2002-05-31
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis
NCT01038739
Evaluation of Efficacy of Mesalamine in the Long-term Prevention of Diverticulitis Flares
NCT01120340
Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis
NCT00744016
OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis
NCT00449722
TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)
NCT01745770
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
3x1000mg placebo granules per day
Mesalamine
Mesalamine
3x1000mg mesalamine granules per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mesalamine
3x1000mg mesalamine granules per day
Placebo
3x1000mg placebo granules per day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Lower abdominal pain of moderate or severe intensity at least during the last 4 days before study inclusion
Exclusion Criteria
* Fever or other signs of serious complications.
45 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Falk Pharma GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wolfgang Kruis, MD
Role: PRINCIPAL_INVESTIGATOR
Ev. Krankenhaus Kalk, University of Cologne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ev. Krankenhaus Kalk, University of Cologne
Cologne, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kruis W, Meier E, Schumacher M, Mickisch O, Greinwald R, Mueller R; German SAG-20 Study Group. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon--a placebo-controlled study. Aliment Pharmacol Ther. 2013 Apr;37(7):680-90. doi: 10.1111/apt.12248. Epub 2013 Feb 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAG-20/DIV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.